Skip to main content
. 2024 May 7;27(6):109921. doi: 10.1016/j.isci.2024.109921

Figure 3.

Figure 3

PIK3CB predicts clinical outcomes of MGMT-deficient GBMs

RNA-seq/RPPA data and associated clinical data were retrieved from TCGA, CGGA, and other GBM datasets downloaded from the GlioVis online program. Results from primary MGMT-deficient/IDH-wt gliomas were pooled together for Kaplan-Meier survival analyses using JMP and Prism 10. Plotted are the resulting HRs with 95% CIs (HR > 1: more chance of death; HR < 1: more chance of survival).

(A) Comparison of high and low levels of PI3K kinases in primary MGMT-deficient/IDH-wt or MGMT-positive/IDH-wt GII/III or GBM patients.

(B) Comparison of high or low levels of pAKTs in primary MGMT-deficient/IDH-wt or MGMT-positive/IDH-wt GII/III or GBM patients.

(C) Comparison of untreated (Chemo–) and treated (Chemo+) cases in primary MGMT-deficient/IDH-wt or MGMT-positive/IDH-wt GII/III or GBM patients expressing various levels of PI3K kinases. Representative Kaplan-Meir survival curves in MGMT-deficient GBMs are shown. Other Kaplan-Meir survival curves can be found in Figures S12–S14. HRs, Log Rank Ps (long-term survival), and Wilcoxon Ps (short-term survival) with 95% CIs are shown. Only statistically significant HRs are marked with ∗. ∗: p < 0.05.